Nature Reviews Drug Discovery

Article	Citations
AI serves up target and inhibitor for lung fibrosis	2386
Vaccine exposes tumours to immune cell attack	1383
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	904
A specific biomarker for insoluble tau	777
Targeting tumour-associated bacteria	611
A new path to targeted protein degradation?	585
Neutralizing Zika virus	580
The improving benefit–risk balance of phase I cancer trials	571
FDA approves a c-MET-targeted ADC for lung cancer	539
Tumour cells get a dendritic cell makeover	514
Glucose-sensitive insulin protects against hypoglycaemia	492
Promoting tissue repair after heart attack	471
mRNA-encoded monoclonal antibody fights CHIKV	434
Hypoimmune iPSCs escape immune detection	412
Lipid nanoparticle ferries therapeutic mRNA to the placenta	374
FDA new drug approvals in Q1 2023	373
Apolipoprotein L2 inhibitor mitigates fibrosis	368
Degrading cell-free DNA to prevent recurrent stroke	349
FDA approves second TTR stabilizer for cardiac amyloidosis	326
Anti-tau antibody stumbles in phase II Alzheimer trial	323
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	310
New antibiotic for urinary tract infections nabs FDA approval	309
Chemical engineering of CRISPR–Cas systems for therapeutic application	302
Targeting drug-resistant glioblastoma	294
Evolution of innovative drug R&D in China	290

2022 FDA approvals	285
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	280
mRNA vaccines for infectious diseases — advances, challenges and opportunities	272
Small-molecule discovery through DNA-encoded libraries	265
Top companies and drugs by sales in 2021	257
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	253
Targeting the Hippo pathway in cancer	247
Increasing the potency of T cell therapies	242
Small molecule improves muscle function in myasthenia gravis	234
Blocking breast cancer metastasis	225
Pushing both sides of the drug pricing aisle	214
Host-directed antiviral blocks SARS-CoV-2 entry	210
TCR-engineered T cells get personal	207
FDA new drug approvals in Q2 2023	205
Inhibiting ASGR1 boosts cholesterol removal	198
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	184
R&D re-balancing act	176
Rewired proteostasis in KRAS inhibitor resistance	176
Screening ultra-large virtual libraries	175
A call to action for translational sciences in COVID-19 and future pandemics	168
Mimicking the health benefits of exercise	166
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	162
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	161
FDA approves second BCMA-targeted CAR-T cell therapy	160
Reflections on 10 years of the FDA’s breakthrough therapy designation	155
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	152
Combating antimicrobial resistance in malaria, HIV and tuberculosis	148
Amylin takes another shot at the obesity prize	146
The significance of blockbusters in the pharmaceutical industry	144
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	142
Base editors hit the clinic	141
Pan-coronavirus vaccine pipeline takes form	127
The emerging role of mass spectrometry-based proteomics in drug discovery	123
Phenotypic drug discovery: recent successes, lessons learned and new directions	120
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	111
Antibody–drug conjugates come of age in oncology	110
The antibody–drug conjugate landscape	109
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	108
Multi-TACs target solid tumours	107
Immunology on the brain	104
Gut metabolite mediates nerve repair	102
Reducing IL-2 toxicity	101
Agonist antibody lowers blood pressure	100
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	99
Monkeypox mRNA vaccine protects mice and macaques	98
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	97
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	91
Neglected tropical diseases go global	91
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	89
Anti-IL-11 antibody shows anti-ageing properties	89

LRRK2-targeted Parkinson disease drug advances into phase III	89
Designing G-protein-selective allosteric modulators	88
Ribosome inhibitor combats bacterial drug resistance	88
The European Innovation Network as a hub for medicines innovation in Europe	87
The malignant melanoma market	82
Targeting the ECM in melanoma	80
Frameworks for transformational breakthroughs in RNA-based medicines	79
Engineered parasite delivers proteins to the brain	77
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	77
Avidity in antibody effector functions and biotherapeutic drug design	77
Delivering genome editing tools to primary cells	76
Engineering a compact genome-editing tool	76
RNA structure guides antiviral ASO design	75
Covalent inhibitor engages oncogenic AKT kinase	74
Upcoming market catalysts in Q4 2023	74
A rush of CRISPR to the lungs	73
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	71
Publisher Correction: Roflumilast	68
Investigating the origins of recent pharmaceutical innovation	66
MYC in cancer: from undruggable target to clinical trials	66
Targeting protein disorder: the next hurdle in drug discovery	65
Broader horizons for cereblon glue degraders	63
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	61
Trends in the development of cellular and gene therapy in China	58
Accelerating precision oncology by converging pragmatic trials and real-world evidence	54
Promoting efferocytosis heals diabetic wounds	54
AAV-based in vivo gene therapy for neurological disorders	53
The non-small-cell lung cancer drug market	50
FDA approves first PSMA-targeted radiopharmaceutical	50
Identification of neoantigens for individualized therapeutic cancer vaccines	47
A bacteria-derived oral tumour vaccine	46
Three-step cures for autoimmune diseases?	46
V-ATPase inhibitor targets Ras-mutant cancers	44
RNA delivery heats up cold tumours	44
Designing novel macrocyclic drugs	43
Upcoming market catalysts in Q4 2024	43
Can large, simple trials bring drug developers back to common diseases?	43
Towards a broad-spectrum antiviral agent	42
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	40
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	40
Microbial ‘dark matter’ yields new antibiotic	40
Analysis of China-to-West pharmaceutical licensing deals in 2024	39
Understanding LAG3 immune checkpoint function	39
De novo design of macrocycles	39
FDA approves cell-sheet-based gene therapy for severe skin disease	38
A new drug target for NRAS(Q61) mutant-expressing cancers	37
Hinge modifier approach opens door to drugging HECT E3 ligases	37
2023 FDA approvals: unprecedented volume at moderate value	36
Glue-based KRAS inhibitors make their debut cancer trial mark	35
RNA chemistry and therapeutics	33
Neurotensin receptor modulator safely tackles pain	33
The case for cell-penetrating peptides	33
The evolution of the obesity drug market	32
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	32
Halda secures biggest induced-proximity deal yet, with J&J’s US$3 billion buy out	32
Therapeutically harnessing extracellular vesicles	32
PPAR agonists provide new treatment options for inflammatory liver disease	32
Novel strategies to manage CAR-T cell toxicity	31
Cartilage regeneration for osteoarthritis	29
A faster route to antidepressant activity	28
Refining HIV pre-exposure prophylactic agents	28
Transcription reprogramming to enhance CAR-T cell function	28
Synthetic cytokine circuit targets solid tumours	28
Targeting sigma receptor 1 in long QT syndrome	28
Designing closure-stabilizing integrin inhibitors	27
miR-21 antagomir reverses COPD pathology	27
A step closer to in vivo editing of haematopoietic stem cells	26
Designing a novel synthetic receptor	26
Novel schizophrenia therapy filed for FDA approval	26
PD1 × VEGF blocking bispecifics for cancer draw big backing	25
FDA approves first factor XIIa inhibitor, for hereditary angioedema	25
FDA approves 21-valent pneumococcal vaccine	25
Enhancing CAR-T cell efficacy through IFN ablation	25
FDA approves PI3Kα inhibitor that does double duty as a degrader	24
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	24
Improving efficacy of ASO therapy in SMA	24
FDA approves decades-old maribavir for CMV infection	24
CAR T cells take to the airways	23
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	22
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety	22

Genome-editing medicinal products: the EMA perspective	22
Sequential immunotherapy: towards cures for autoimmunity	21
In vivo CAR T cells move into clinical trials	21
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	21
Unmet needs in vaccine development	20
Anti-histamines boost immunotherapy	20
Top product forecasts for 2025	19
Rebalancing cardiolipin biosynthesis to treat cardiomyopathy	19
Targeting galectin-driven regulatory circuits in cancer and fibrosis	19
Drugging the efferocytosis process: concepts and opportunities	19
RNAi-based drug design: considerations and future directions	19
Designing insulin receptor agonists	18
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	18
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	18
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	17
Synthesizing portimines	17
Stalled molecular motor inhibits tumour growth	17
Acyl-lysine reader inhibitor blocks AML progression	17
Epigenetic editor silences prion protein	17
Bacteria tag tumours for CAR-T cell attack	17
Understanding the effects of antibiotic combinations	17
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	17
Open-science drug discovery for COVID-19	17
Treating cannabis use disorder	17
Trustworthy AI for safe medicines	16
Building on the momentum of N-of-1 base editor therapies for rare diseases	16
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	16
Lilly buys Verve and its in vivo gene editors for up to US$1.3 billion	16
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning	16
ASO targets DNA repair protein to combat Huntington disease	16
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	16
Brain glucose mediates amphotericin B tolerance	16
Neurons give metastatic cells a push	16
In vivo CAR T cells gain traction, with AbbVie’s US$2.1 billion acquisition of Capstan Therapeutics	16
CRISPR activation tackles neurodevelopmental disorders	16
Bispecific antibodies in oncology	15
Thinking outside the box: non-canonical targets in multiple sclerosis	15
opnMe.com: a digital initiative for sharing tools with the biomedical research community	15
The KRAS crowd targets its next cancer mutations	15
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	15
Insights into new approach methodology innovation: an EMA perspective	15
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	15
Understanding sphingosine-1-phosphate transport	14
Trends in the drug target landscape for autoimmune diseases	14
Gene editing addresses antithrombin deficiency	14
Advanced technologies for the development of infectious disease vaccines	14
Alnylam scores big pharma support for angiotensinogen silencer	14
A new antibiotic for A. baumannii	13
Soluble Notch agonists drive T cell production	12
Hooking FSH as a potential target for Alzheimer disease	12
FDA releases tissue-agnostic cancer drug draft guidance	12
Setting GPCRs free	12
The renal cell carcinoma drug market	12
Understanding immunomodulatory antibody agonism	12
Upcoming market catalysts in Q3 2023	12
Ramping up mitochondrial DNA replication	12
Top product forecasts for 2022	11
FDA approves first two drugs for rare Niemann–Pick disease	11
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	11
Targeting cytokine networks in neuroinflammatory diseases	11
FDA approves first claudin-18.2-targeted antibody for gastric cancer	11
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities	11
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial	11
Antibody cocktail eliminates ebolaviruses	11
FDA approves first chikungunya vaccine	11
Phosphatase inhibitor drives anticancer immune responses	11
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	11
Macrophages as tools and targets in cancer therapy	10
Membrane transporters in drug development and as determinants of precision medicine	10
Targeting ephrin signalling in sepsis	10
Targeting ALDH1B1 in colorectal cancer	10
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	10
Two-pronged approach for macular degeneration	10
Inhibiting metallo-β-lactamases	10
DUBTACs for targeted protein stabilization	10
Targeting expanded trinucleotide repeats	10
mRNA vaccine for Lyme disease prevention	10
New route to target RAS	9
BacPROTAC to treat tuberculosis	9
Chromatin-targeted drug discovery at “a very special moment”	9
New therapeutic candidate for Chagas disease	9
Antibody drug conjugate combats inflammation	9
Mapping cysteine ligandability	9
Repurposing beta-blockers in breast cancer	9
FDA approves BTK inhibitor for chronic hives	8
FDA approves PI3K inhibitor for a rare immune disorder	8
Opportunities for mitochondrial disease gene therapy	8
Novel drug targets in 2021	8
RNF41 reverses liver fibrosis	8
Roche buys MASH contender for up to US$3.5 billion	8
The potential of innovative trial design for efficiently evaluating repurposed drugs	8
2022 FDA approval number dips: a COVID-19 hangover?	8
Understanding semaglutide action in the brain	8
FDA approves second anti-amyloid antibody for Alzheimer disease	8
Antibody–oligonucleotide conjugates enter the clinic	8